Live Oral Shigella dysenteriae Vaccine

This application claims a Salmonella typhi Ty21a construct comprising a Shigella dysenteriae O-specific polysaccharide (O-Ps) inserted into the Salmonella typhi Ty21a chromosome, where heterologous Shigella dysenteriae serotype 1 O-antigen is stably expressed together with homologous Salmonella typhi O-antigen. The constructs of this invention elicit immune protection against virulent Shigella dysenteriae challenge, as well as Salmonella typhi challenge. Also claimed in this application are methods of making the constructs of this invention and methods for inducing an immune response. Shigella cause millions of cases of dysentery every year, which result in about seven hundred thousand deaths worldwide. Shigella dysenteriae serotype 1, one of about forty serotypes of Shigella, causes a more severe disease with a much higher mortality rate than other serotypes. There are no licensed vaccines available for protection against Shigella. The fact that many isolates exhibit multiple antibiotic resistance complicates the management of dysentery infections. IC:  FDA NIH Ref. No.:  E-214-2004/0 TAB No:  TAB-2527 Advantages: Vector is well-characterized. Simple manufacturing process. Potential low-cost vaccine. Oral vaccine – avoids need for needles. Temperature-stable formulation allows for vaccine distribution without refrigeration. Applicati...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research